Pyrazolotriazines as kinase inhibitors

1. A compound represented by the structural formula:

or a pharmaceutically acceptable salt, or ester of said compound, wherein:

R 1 is selected from the group consisting of H, alkyl, aryl, heteroaryl, heteroarylalkyl, arylalkyl, NR 6 R 7 , cycloalkyl and cycloalkylalkyl, wherein each of said alkyl, aryl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl and arylalkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each being independently selected from the group consisting of halo, alkyl, aryl, heteroaryl, heterocyclyl, trifluoromethyl, OR 6 , NR 6 R 7 , SR 8 , SO 2 R 8 , CN, SO 2 N(R 6 R 7 ) and NO 2 ;

R 2 is aikyl, cycloalkyl, alkenyl, alkynyl, trifluoromethyl, —OR 7 , —SR 7 , hydroxyalkyl, haloalkyl, aryl, heteroaryl, halo, CN, formyl, nitro, alkylcarbonyl, alkylcarbonyl, heteroaralkylcarbonyl, or alkylene-N(R 8 R 9 ) (where R 8 and R 9 independently represent H or alkyl, or R 8 and R 9 taken together with the nitrogen in —N(R 8 R 9 ) form a five- to seven-membered heterocycle);

R 3 is —NR 4 R 5 ,

 alkyl, alkyithio, aralkylthia, alkylsulfinyl, or araikylsulfinyl;

R 4 is aikyl, cycloalkyl or hetemoyclyl, wherein each of said alkyl, cycloalkyl and heterocyclyl can be unsubstituted or optionally independently substituted with 1–4 substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, trifluoromethyl, OR 6 , NR 6 R 7 , SR 6 , SO 2 R 6 , CN, SO 2 N(R6R7) and NO 2 ;

R 5 is H, alkyl, ary, heteroaryl, arylalkyl, cycloalkyl, heterocyclyl, acyl or heteroarylalkyl;

R 6 is H, alkyl or aryl;

R 7 is H oralkyl;

R 10 is halo, alkyl, hydroxyalkyl, trifluoromethyl, OR 6 , NR 6 R 7 , SR 6 , SO 2 R 6 , CN, SO 2 N(R 6 R 7 ) or NO 2 ; and

n is 0 to 4, and when n is 2–4, the n moieties can be the same or different, each being independently selected, with the following provisos:

(i) that when R 2 is C 1 –C 4 alkyl and R 5 is H, then R 4 is not a C 1 –C 4 alkyl;

(ii) that when R 2 is halo, CN, formyl, nitro, alkylcarbonyl, alkylcarbonyl, heteroaralkylcarbonyl, or -alkylene-N(R 8 R 9 ), then: (a) R 3 is not H, alkylthio, aralkylthlo, alkylsulflnyl, aralkylsulfinyl, or —NR 4 R 5 , and (b) n is not 0; and

(iii) that when R 2 is alkyl, cycloalkyl, alkenyl or alkynyl, then R 3 is not NH(methyl), N,N(dimethyl), NH(acetyl), N(methyl)(acetyl), H, alkyl, alkyithio, aralkyithio, alkylsulflnyl, or aralkylsulfinyl.

2. The compound of claim 1 , wherein R 1 is selected from alkyl, aryt, heteroaryt, heteroarylalkyl, arylalkyl or NR 6 R 7 wherein each of said alkyl, aryl, heteroaryl, hetemarylalkyl and arylalkyl can be unsubstituted or optionally independently substituted with one or more substituents which can be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, aryl, heteroaryl, trifluoromethyl, OR 5 , NR 6 R 7 , SR 6 , SO 2 R 6 , CN, SO 2 N(R 6 R 7 ) and NO 2 .

3. The compound of claim 1 , wherein R 2 is alkyl, cycloalkyl, alkynyl, trifluoromethyl, —OR 7 , or —SR 7 .

4. The compound of claim 1 , wherein R 3 is NR 4 R 5 ,

5. The compound of claim 1 , wherein R 4 is alkyl, cycloalkyl or heterocyclyl, wherein each of said alkyl, cycloalkyl or heterocyclyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halo, alkyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, trifluoromethyl, OR 6 , NR 6 R 7 , SR 6 , SO 2 R 6 , CN, SO 2 N(R 6 R 7 )and NO 2 .

6. The compound of claim 1 , wherein R 5 is H, alkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl.

7. The compound of claim 1 , wherein n is 1 to 2.

8. The compound of claim 1 , wherein R 6 is H, alkyl or aryl.

9. The compound of claim 1 , wherein R 7 is H or alkyl.

10. The compound of claim 1 , wherein R 10 is halo, alkyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, trifluoromethyl, OH, NR 6 R 7 , SR 6 , SO 2 R 6 , CN or SO 2 NR 6 R 7 .

11. The compound of claim 2 , wherein R 1 is selected from the group consisting of phenyl, imidazolyl, imidazolyl-N-oxide, pyridyl, pyridyl-N-oxide, pyrazinyl, pyrazinyl-N-oxide, phenethyl, pyridone, —(CH 2 )-pyridyl, —(CH 2 )-pyridyl-N-oxide, —(CH 2 )-pyrazinyl, —(CH2)-pyrazinyl-N-oxide, —(CH 2 )-pyridone, and —(CH 2 )-imidazolyl-N-oxide, wherein each of said phenyl, imidazolyl, pyridyl, pyridone, and pyrazinyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halo, methyl, ethyl, trlfluoromethyl, OH, alkoxy, NH 2 , SH, SO 2 CH 3 , CN and SO 2 NH(CH 2 ) 2 CH 3 .

12. The compound of claim 3 , wherein R 2 is selected from the group consisting of methyl, ethyl, cyclopropyl, cyclobutyl, cyclopentyl, ethenyl, —CF 3 hydroxy, methoxy, and ethoxy.

13. The compound of claim 7 , wherein n is 1.

14. The compound of claim 4 , wherein R 3 is selected from the group consisting of:

(i) piperidyl substituted with a hydroxymethyl or hydroxyethyl;

(ii) pyrazinyl substituted with a hydroxymethyl or hydroxyethyi;

(iii) pyrrolidinyl substituted with a hydroxymethyl or hydroxysthyl;

(iv) cyclohexyl substituted with a hydroxymethyl or hydroxyathyl;

(v) cyclopentyl substituted with a hydroxymethyl or hydroxyethyl);

(vi)—N(H)(piperldyl substituted with a hydroxymethyl or hydroxyethyl);

(vii)—N(H)(cyclohexyl substituted with a hydroxymethyl or hydroxyethyl);

(viii)—N(H)(cyclopentyl substituted with a hydroxymethyl or hydroxyethyl);

(ix)—N(H)(pyrrolidinyl substituted with a hydroxymethyl or hydroxyethyl); and

(x)—N(H )[CH(hydroxymethyl)(isopropyl)].

15. The compound of claim 5 , wherein R 4 is alkyl or cycloalkyl.

16. The compound of claim 6 , wherein R 5 is H.

17. The compound of claim 8 , wherein R 8 is H or alkyl.

18. The compound of claim 9 , wherein R 7 is alkyl.

19. The compound of claim 10 , wherein R 10 is hydroxymethyl or hydroxyethyl.

20. The compound of claim 1 , wherein:

R 1 is selected from the group consisting of imidazolyl, imidazolyl-N-oxide, pyridyl, pyridyl-N-oxide, pyrazinyl, pyrazinyl-N-oxide, phenethyl, pyridone, —(CH 2 )-pyridyl, —(CH 2 )-pyridyl-N-oxlde, —(CH 2 )-pyrazinyl, —(CH 2 )-pyridone, and —(CH 2 )-pyrazinyl-N-oxide;

R 2 is selected from the group consisting of methyl, ethyl and cyclopropyl; n is 1;

R 3 is selected from the group consisting of:

(i) pipendyl substituted with a hydroxymethyl or hydroxyethyl;

(ii) pyrazinyl substituted with a hydroxymethyl or hydroxyethyl;

(iii) pyrrolidinyl substituted with a hydroxymethyl or hydroxyethyl;

(iv) cyclohexyl substituted with a hydroxymethyl or hydroxyethyl;

(v) cyclopentyl substituted with a hydroxymethyl or hydroxyethyl);

(vi)—N(H)(piperidyl substituted with a hydroxymethyl or hydroxyethyl);

(vii)—N(H)(cyclohexyl substituted with a hydroxymethyl or hydroxyathyl);

(viii)—N(H)(cyclopentyl substituted with a hydroxymethyl or hydroxyethyl),

(ix)—N(H)(pyrrolidinyl substituted with a hydroxymethyl or hydroxyethyl); and

(x)—N(H)[C H(hydroxymethyl)(isopropyl)];

R 4 is alkyl or cycloalkyl;

R 5 is H;

R 6 is H or alkyl; and

R 7 is alkyl.

21. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt, or ester thereof.

22. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt, or ester thereof.